Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

PERAMPANEL

Drug and asset intelligence for PERAMPANEL with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Sponsor company

TARO Pharmaceuticals →

Recent signals(1)

RegulatoryJune 18, 2026

TARO's ANDA219052 for PERAMPANEL Receives Approval Status

TARO's ANDA219052 for PERAMPANEL has received an approval status (AP) from the FDA.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

TARO Pharmaceuticals — PERAMPANEL

Monitor for the final approval decision and subsequent market entry timelines for TARO's PERAMPANEL.

June 18, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Anticonvulsant →
Neurology →
Neurology · Anticonvulsant →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.